Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin Paclitaxel Combined With Cisplatin and Radiotherapy in Stage III NSCLC
NCT04284215Unknown
- Sponsor
- Guizhou Medical University
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of nab-paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guizhou Medical University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
nab-paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04284215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04284215.